22nd IFPMA Assembly
27 - 29 October 2004
13:30 to 12:30
Hotel Arts, Barcelona, Spain
This event has now passed. To browse our upcoming events click here.
PATIENTS, PARTNERSHIPS AND THE PHARMACEUTICAL INNOVATION PLATFORM
• Partnerships in the fight against HIV/AIDS
• Innovation, Competitiveness, Access and Sustainability
• The Pharmaceutical Innovation Platform
• Ensuring High Standards for Access to Safe Medicines
• The Right to Information
• Partnerships for New Medicines and Vaccines for the Developing World
• The Evolving Role of NGOs
• Partnerships with Multilateral Organizations
• Open Markets for Better Health
The Pharmaceutical Innovation Platform –
New medicines, vaccines and other medical tools have revolutionized medical
practice in the past century, leading to incredible health improvements, as well as
profound social and economic changes globally. The demographic and
epidemiological evolution necessitates on-going efforts to develop new and
improved medicines that could better serve the health needs of patients. Progress in
medicines is largely generated by the research-based pharmaceutical companies
that have accumulated the unique skills, capacities and expertise needed to
successfully conduct the complex, lengthy and costly process of pharmaceutical
R&D. However, public policies and regulations largely determine the performance of
these companies and thus directly influence the pace of medicines innovation. This
session features a new report from IFPMA – ‘Pharmaceutical Innovation Platform:
Sustaining Better Health for Patients Worldwide’ which describes the complex
environment enabling pharmaceutical innovation.
Innovation, Competitiveness, Access and Sustainability –
Preserving the innovation capacity of the pharmaceutical industry should be an
important consideration for national authorities responsible for designing public
health policies. Innovation in medicines provides patients with medical solutions
adapted to their evolving health needs which enable a more efficient and efficacious
allocation of resources by governments and health insurers. Achieving an optimal
equilibrium between health and industry policy presents an important challenge that
can be best faced through an open and constructive dialogue between government
and industry policy makers. This session presents the policy framework in Spain,
advocating for better understanding of the value of innovation in medicines as well as
the underlying government policies and regulations that determine this innovation.
Partnerships in the fight against HIV/AIDS –
HIV/AIDS represents an unprecedented health, social and economic burden.
Combating this terrible disease must cover various grounds such as education,
training, prevention, counseling, treatment and care, and requires combined efforts
of various actors to succeed. The fight against HIV/AIDS requires the coordination of
all actors, including patient organizations, health care professionals, local
communities, civil society organizations, governments, UN agencies, and
pharmaceutical companies. These collaborative efforts spread over all critical
aspects of the HIV/AIDS pandemic and represent a crucial contribution to the global
strategy to address this enormous health challenge. This session is an opportunity to
share experiences from various partnerships fighting HIV/AIDS.
Welcome Reception sponsored by IMS Health
Ensuring Access to Safe and Effective Medicines –
Pharmaceutical products are subject to stringent control in terms of their quality and
efficacy in order to assure that patients are not exposed to potentially hazardous and
harmful substances. Unfortunately, substandard and counterfeit medicines are
increasingly found in official distribution channels, both in developed and developing
countries. These ineffective and often unsafe products represent a serious public
health threat on the global scale. This session elaborates the need for a joint
collaborative effort of different stakeholders to effectively address this growing
Right to Information –
The galloping evolution of communication technologies has had a phenomenal
impact on access to knowledge and information worldwide, improving people’s
overall skills and capacities. This important benefit of the global information society
has so far failed to fully materialize in the area of health. In most countries, patients
still lack adequate access to valid health information, particularly regarding existing
prevention and treatment options. Consequently, the level of their health literacy is far
from optimal, which works to the disadvantage of patients, physicians and healthcare
systems overall. This session focuses on the critical role of adequate health
information in improving health status of patients and the functioning of healthcare
systems in general.
Lunch sponsored by Merck & Co., Inc.
Partnerships in Developing Medicines for Neglected Populations –
The health needs of poor populations present a particular challenge for the
international health community. Many diseases affecting these populations are
almost exclusively prevalent in developing countries that lack necessary resources,
infrastructure and stability to establish proper healthcare systems and ensure access
to even most basic medical interventions. The development of new drugs for some
of these diseases consequently requires contributions and support of various
stakeholders, including public research institutions, governments, international
organizations, foundations, civil society organizations and the pharmaceutical
industry. This session features several existing initiatives established to develop
needed drugs for poor populations based on public-private collaboration.
It examines the challenges and lessons learnt and explores the need for further
collaborative efforts to improve the chances for new drugs for poor patients in need.
The Evolving Role of NGOs –
The international health community has seen some important changes over the last
two decades that can be broadly characterized by the growing proliferation of
players. Most importantly, the emergence of diverse forms of organization such as
non-governmental organizations and multi-stakeholder partnerships have influenced
the way in which health problems are addressed today. Mobilizing different
stakeholders and working closely with patients and local communities, these
organizations have managed to apply novel approaches yielding promising results
both at the policy and at the health care provision levels. Consequently, they have
become key contributors to the global health efforts and debates. This session
discusses the growing importance of these different organizations as legitimate
public health players.
Dinner sponsored by Farmaindustria
Emerging Regional Issues – Asia, Latin America, Central Eastern Europe –
Looking into the future of the pharmaceutical industry, important attention is given to
the major emerging and developing countries, as both future growth markets and
potential contributors to the global R&D endeavors. The implementation of the TRIPS
Agreement has already initiated important changes in countries such as India and
China where generic companies increasingly view the need for R&D investments as
the business development strategy to pursue in the future. However, such positive
signs are too often overshadowed by negative developments that occur on the level
of government policies affecting the pharmaceutical industry. Such policies
drastically impact the basic operating environment of the industry and can impede
both its growth and innovation capacities. However, constructive policies can also
promote investment by the industry in developing country markets. This session
reviews different new trends that emerge in major developing and emerging markets
and discusses their potential implications.
Open Markets for Better Health –
Efficient markets are critical to sustaining the pharmaceutical industry’s investmentinnovation
cycle and safeguarding the continued discovery and development of new
medicines and vaccines. Too often, restrictive policies tend to limit the efficient
operation of these markets by imposing various cost containment measures
targeting pharmaceutical prices alone, without considering the unintended
consequences for maintaining an enabling environment for innovation. Increasing
government interventions and a lack of flexibility in the way pharmaceutical markets
operate in major countries have already resulted in a deteriorating investment climate
and increased risk of further impediments to needed pharmaceutical innovation. This
session presents the arguments in favor of open and efficient markets as a major
determinant of the pharmaceutical industry’s competitiveness and its ability to
Closing remarks by Mr. Raymond V. Gilmartin, Chairman, President and CEO, Merck & Co., Inc.
Lunch sponsored by Novartis
Dr. Carol Adelman is currently a senior fellow at the Hudson Institute where she lectures and
writes on global healthcare issues, foreign aid, and international development. Dr. Adelman was
a career foreign service officer with the U.S. Agency for International Development (USAID), living
and working in Africa and assisting governments in Latin America and Asia. Dr. Adelman served
as an Assistant Administrator at USAID, in charge of all agency programs in Asia, the Middle East,
and Central and Eastern Europe. She is Vice Chairman of the Atlantic Council, a member of the
Council on Foreign Relations, and is a frequent participant in foreign affairs and global
development seminars and media events. Author of many articles, Dr. Adelman has published in
Foreign Affairs, Lancet, the Wall Street Journal, American Outlook, Christian Science Monitor, and
Policy Review. Dr. Adelman received her Doctorate and Masters in Public Health from Johns
Hopkins University. She also holds a Masters in Foreign Service from Georgetown University and
completed her undergraduate degree at the University of Colorado and the University of Bonn,
Dr. Hatsuo Aoki is the President and CEO of Fujisawa Pharmaceutical Co., Ltd. He is in current
position since June 1999. He experienced the Chairman and CEO of Fujisawa’s US subsidiary
from 1993 through 1995 and took the office of President of New York Pharma Forum for one year
while he was in the US. He has a scientific background with a doctorate in agricultural chemistry
from the University of Tokyo and deeply involved in the research and development of tacrolimus,
the Fujisawa’s breakthrough immunosuppressant. Tacrolimus is currently available as Prograf, an
immunosuppressant for organ rejection in organ transplant in almost 70 countries and as
Protopic for the treatment of atopic dermatitis in 30 countries worldwide.
Mr. Arnés Corellano holds a Degree in Industrial Engineering and graduated from the Technical
High School of Industrial Engineers in Barcelona in 1975. Shortly after qualifying, Mr. Arnés started
his professional career working for the Ministry of Industry and Energy. Mr. Arnés has held several
prestigious positions in his career to-date. He was a Director for the Pharmaceutical Industries,
a Director of a Biotech and Chemical technologies Company, Director General of the Industrial
Technological Development Centre (CDTI) and Director General of the Institute of Regional
Promotions, Principality of Asturias (IFR). Since 2001 he holds the position of Director General
of Farmaindustria (National Association of Pharmaceutical Industrial Companies).
Dr. Anarfi Asamoah-Baah, from Ghana, is the Executive Director for Health Technology and
Pharmaceuticals at the World Health Organization. He has been working in WHO since 1998
when he was first appointed as a senior policy advisor to the Director-General. In July 2000 he
was appointed the Executive Director, External Relations and Governing Bodies of WHO. Before
joining WHO, Dr. Asamoah-Baah was the Director of Medical Services for Ghana. Initially trained
as a doctor with special interest in paediatrics, he started his career as a physician in charge of
a small clinic in a rural province of Ghana where he developed interest in public health.
Dr. Asamoah-Baah obtained post-graduate qualifications in community health, health planning,
health economics and policy analysis during his studies in the UK and the US.
William Babumba is the current chair and founder member of Community Health and Information
Network (CHAIN) and a member of the European AIDS Treatment Group (EATG). William is a
trained Laboratory haematologist by profession and has worked in a number of organisations
both in the UK and in Africa. CHAIN is an international project, which lobbies for increased access
to ARVs, drugs for opportunistic infections and adequate treatment education for people living
with HIV/AIDS in developing countries. CHAIN’s current focus is in the Great Lakes Region where it
is running a capacity building programme aimed at building strong institutions of People Living
Mary G. Baker, MBE, is President of the European Federation of Neurological Associations,
the European Parkinson’s Disease Association, Vice President of the European Brain Council,
Consultant to the World Health Organisation (WHO) and Chair of the Working Group on
Parkinson’s Disease, formed by the WHO in May 1997. She is Director at Large for the World
Stroke Association, patient editor of the BMJ, member of the ABPI Code of Practice and has
received an Honorary Doctorate from the University of Surrey in recognition of her work within the
world of Parkinson’s disease. Mary has also received numerous awards in recognition of her work
in the field of Neurology, and PD in particular, including the European Woman of Achievement
Award 2000, and the Human Communication International Award 2001.
Dr. Harvey E. Bale, Jr. is the Director-General of the International Federation of Pharmaceutical
Manufacturers Associations, IFPMA. Previously he was Senior Vice President for International
Affairs with the Pharmaceutical Research and Manufacturers of America. Prior to that he was
International Manager at Hewlett-Packard. He also served 12 years in the Office of the U.S. Trade
Representative. In 1980 he was on special White House assignment to the Middle East Camp
David negotiations. In 1986 he received the Distinguished Service Award from President of the
United States Ronald Reagan. In 1996-1997 he taught a post-graduate course on intellectual
property and technology strategy at Georgetown University. Dr. Bale received a Ph.D. in
economics from University of Maryland and a B.A. from Temple University.
Richard Burzynski is a Canadian AIDS activist who has worked in the AIDS field for over 20 years
at the local, national and international levels in the areas of advocacy and policy development.
Currently, he is the Executive Director of the International Council of AIDS Service Organizations
(ICASO), an organization he co-founded with other leading AIDS activists over ten years ago.
Through ICASO, Richard has been an advocate for building the capacity of community-based
AIDS service organizations especially in the developing world, and has worked to promote their
agendas with donors, governments, multi-lateral agencies, the private sector, and the media.
A frequent speaker and moderator, he serves as a principal co-organizer of the biennial
international AIDS conferences. Richard helped shape the architecture of the Global Fund to Fight
AIDS, TB and Malaria, and he currently serves as the Communication Focal Point of the
Developed Country NGO delegation. Richard is a frequent advisor to UNAIDS.
Yves Champey is a physician with over 40 years experience in the pharmaceutical industry.
He started as Medical and Scientific Director. He has worked with Miles, Pfizer and Rhone
Poulenc Santé, and was Senior Vice President, International Drug Development, at Rhone
Poulenc, from 1995 to 1997. Yves is a founder of ITEEC and an associate consultant providing
counselling in drug research and development. He is an Advisor to the Director General of Evry
Genopole – a French national project for the development of biotechnology activities, and the
CEO of Genopole Day One – a private seed fund in France. In addition, Yves is a former member
of Rhône-Poulenc Pharma R&D Board of Directors; has been the Secretary General and later
the President of the French Association of Pharmaceutical Physicians ; a Founder and the
President of the Rhône-Poulenc Rorer Foundation; and a member of the Inter-Ministerial Mission
on Public Research and Drug Innovation Research established by the Ministry of Research and
the Ministry of Economy and Finance in France. He is one of the very early proponents of DNDi
and has coordinated its creation.
Dr. Jack C. Chow is the Assistant Director-General of the World Health Organization for HIV/AIDS,
Tuberculosis, and Malaria. Prior to joining WHO, Dr Chow held the rank of ambassador as the
Special Representative of the U.S. Secretary of State for Global HIV/AIDS and as the Deputy
Assistant Secretary of State for Health and Science. Dr Chow previously served in senior
positions at the State Department, Department of Health and Human Services, House and
Senate Appropriations Committees, and the White House Office of Science and Technology
Policy. He was also a management consultant with McKinsey & Company. Dr Chow earned his
M.D. from University of California at San Francisco and trained at Stanford University Hospital.
His other degrees are from Harvard University’s Kennedy School of Government (M.P.A),
University of Chicago (M.B.A.), University of California at Berkeley (M.S.), and University of
Donald de Korte is heading the Expanded Access Programs of Merck & Co., Inc. in Europe,
Middle East, and Africa, supporting governments, development partners, and the private sector
in up-scaling the response to the HIV epidemic. In 2000, Donald established the African
comprehensive HIV/AIDS Partnerships (ACHAP), a collaborative effort between the Bill & Melinda
Gates Foundation, Merck & Co., Inc., the Merck Company Foundation, and the Government of
Botswana. ACHAP is an unique public-private partnership concentrating on the development and
implementation of a national comprehensive HIV/AIDS Strategy in Botswana, a country with the
highest recorded HIV prevalence.
Donald is of Dutch nationality, and holds a Medical Doctor and Bachelor of Science degree
(pharmacology) from the University of Amsterdam, in addition to a Bachelor degree from the
Dutch Institute of Marketing.
Dr. Raul Dejean Rodríguez was born in Buenos Aires, Argentina. He is a lawyer, specialized in
International Economical Affairs and Foreign Trade. He is a member of the Argentine Foreign
Service and is currently holding a post of the National Director of Imports, Undersecretary of
Industry in the Ministry of Economy of Argentina. Throughout his career, Dr. Dejean Rodríguez has
represented Argentina on diplomatic missions in Rome, Barcelona and Madrid. He has an
extensive experience as a government official, having worked for both the Ministry of Foreign
Affairs and the Ministry of Economy for many years.
Dr. Antonio Esteve is a member of the Executive Committee and the Director of Scientific and
Commercial Operations at ESTEVE Group. He is also a Member of the Advisory Board for R&D of
the Spanish Ministry of Science and Technology and the President of CTBT (Centre de
Transfussió i Banc de Teixits). In 1997 he was elected a Member of the Royal Academy
of Pharmacy of Catalonia. He holds a degree in pharmacy and PhD in pharmaceutical science.
Prof. Richard G.A. Feachem, CBE is the Executive Director of The Global Fund to Fight AIDS,
Tuberculosis and Malaria. Prior to this, he was Professor of International Health at the University
of California, San Francisco and Berkeley. Professor Feachem has worked in international health
and development for 30 years and has published extensively on public health and health policy.
In 1995 he was awarded a CBE for services to international health by Her Majesty Queen
Elizabeth II. In 2002 he was elected to membership of the Institute of Medicine.
Dr. Armin Fidler is the Health Sector Manager for Europe and Central Asia at the World Bank and
represents this region on the Bank’s Sector Board for Health, Nutrition and Population. Dr. Fidler
received his MD from the University of Innsbruck, Austria, in 1984, a Diploma in Tropical Medicine
and Hygiene from the Bernhard Nocht Institute at the University of Hamburg, and a MPH in 1989
and an SM in 1990 from the Harvard School of Public Health. In addition, Dr. Fidler is as adjunct
faculty at the George Washington University School of Public Health in Washington, D.C., and
serves on the board of the Open Health Institute in Moscow, a non-governmental organization.
Prior to joining the World Bank, Dr. Fidler worked as sub-regional advisor for the World Health
Organization (PAHO/WHO) in Mexico and Central America and was admitted to the Epidemic
Intelligence Service Program at CDC in Atlanta, Georgia.
Dr. Odile Frank is a Senior Technical Specialist and the Head of Research and Policy Unit of the
International Labour Office (ILO). Her previous positions included the chief of Social Integration
Branch, Division of Social Policy and Development, in the United Nations office in N New York ;
a Statistician and Social Scientist at the World Health Organization (WHO), Geneva ; as Associate
in the Population Council, New York ; an Administrator, at the Organisation for Eeconomic
Cooperation and Development (OECD), Paris ; as well as an Independent Consultant, UNAIDS,
Geneva. Dr. Frank was the principal author and coordinator of the ILO publication, HIV/AIDS and
Work : Global estimates, impact and response published in 2004. She holds a B.Sc in psychology
and economics from London University, and M.Sc and D.Sc. in population studies from Harvard
University School of Public Health.
Dr. Maria C. Freire is the President and Chief Executive Officer of the Global Alliance for TB Drug
Development, a position she has held since 2001. An internationally recognized expert in
technology commercialization, Dr. Freire was appointed in February 2004 to the World Health
Organization’s newly formed Commission on Intellectual Property Rights, Innovation and Public
Health (CIPIH). From 1995 to 2001, Dr. Freire directed the Office of Technology Transfer, U.S.
National Institutes of Health (NIH), where she was responsible for the central development and
implementation of technology transfer policies and procedures for the Department of Health and
Human Services, and for the patenting and licensing activities for the NIH and the Food and Drug
Administration. Prior to that, Dr. Freire established and headed the Office of Technology
Development at the University of Maryland at Baltimore and the University of Maryland Baltimore
County. Born in Lima, Peru, Dr. Freire trained at the Universidad Peruana Cayetano Heredia in
Lima. She obtained her Ph.D. in Biophysics from the University of Virginia and completed postgraduate
work in immunology and virology at the University of Virginia and the University of
Dr. Marina Geli is the Counsellor, Health Policy in the Catalonian Government. She holds a degree
in Medicine from the Barcelona University. She practised as a physician in Josep Trueta Hospital,
Girona, from 1981 till 1990. She is a specialist in infectious diseases, AIDS, community prevention
among others. Dr. Geli is a funding member of several organisations related to AIDS patients’s
care. She has been a member of the Catalonian Parliament since 1995, and a spokesperson for
Social Wellbeing of the Social Policy Committee.
Raymond V. Gilmartin joined Merck & Co., Inc. in June 1994 as president and chief executive
officer. He was named to the additional post of chairman of the board in November 1994. Prior to
joining Merck, Mr. Gilmartin was chairman, president and chief executive officer of Becton
Dickinson and Company. Mr. Gilmartin serves on the boards of directors of General Mills, Inc.
and the Microsoft Corporation. An active participant in health industry affairs, Mr. Gilmartin is
the president of the International Federation of Pharmaceutical Manufacturers Associations.
Mr. Gilmartin also serves on the executive committee of the Pharmaceutical Research &
Manufacturers of America. On February 26, 2003, Mr. Gilmartin was sworn in by President
George W. Bush as a member of the President’s Export Council, and he also serves as a
member of the Trans Atlantic Business Dialogue and the Trade and Poverty Forum.
James K. Glassman is host of TechCentralStation.com, a public affairs website that concentrates
on matters of technology and a public policy resident fellow at the American Enterprise Institute,
a Washington public policy think tank, where he specializes in issues involving economics,
technology and financial markets. He is also a syndicated columnist for Scripps Howard News
Service and writes a syndicated financial column, which appears on the front page of the
business section of the Washington Post every Sunday and is published in other newspapers,
including the New York Daily News and the International Herald Tribune. Mr. Glassman has had
extensive magazine publishing and television experience in the US. His articles have appeared
in The Wall Street Journal, Reader’s Digest, Forbes, the New York Times, the Los Angeles Times,
and others. Mr. Glassman has given frequent congressional testimony, recently on subjects as
varied as telecommunications policy, Securities and Exchange Commission regulations, Social
Security reform, and personal investing. He is a graduate of Harvard University, where he was
managing editor of the university daily, The Crimson.
Prof. Trevor Jones is a Director of Allergan Inc and Senior R&D advisor to Esteve Spa. For 10 years
until September 2004 he was Director General of the Association of the British Pharmaceutical
Industry (ABPI). He is Deputy Chairman of Council and visiting professor at King’s College,
University of London and has been awarded honorary doctorates from five universities. Prof
Jones is Scientific Director and Chairman of the Scientific Advisory Board of the venture capital
business, Merlin Biosciences, and Chairman of the stem cell biotech company, ReNeuron. From
1987-94, he was a main board director of The Wellcome Foundation, where he was responsible
for R&D including the development of AZT, Zovirax and other medicines. He is a founder member
of the Geneva-based, public : private partnership, Medicines for Malaria Venture (MMV) and in
2004 was appointed to the World Health Organisation (WHO) Commission on Intellectual
Property Rights and International Health (C.I.P.I.H). He was honoured by Her Majesty the Queen
by the award of CBE in the 2003 New Year’s Honours List.
Dr. Albert J. Jovell is the Chief Executive Officer of the Josep Laporte’s Library Foundation and
Associate Professor of the Department of Preventive Medicine and Public Health of the School of
Medicine of the University Autonoma of Barcelona. He is also director of the Observatory for
Woman and Health, Webpacientes, Jaime Rotes Querol Library, and Clinical Management Library.
Dr. Jovell holds an MD and a PhD in Sociology from University of Barcelona (Spain) ; a Master of
Public Health (MPH) in Epidemiology, a Master of Science (MS) in Health Policy and Management,
and a Doctor of Public Health (DPH) degrees from Harvard University (USA), and a MA degree in
Political and Social Sciences from the University Autonoma of Barcelona (Spain). He is also
specialist in Preventive Medicine and Public Health by Spanish Government. He was head of the
Research and Academic Unit of the Catalan Agency for Health Technology Assessment (CATHA),
a non-profit public agency in the Department of Health and Social Security of Catalonia, Spain.
Thomas Kubic is a former Federal law enforcement executive with national and international
investigative experience. Since 2002, he has worked closely with a new PSI Board of Directors
and the Members to insure the integrity of pharmaceuticals. Under his leadership, PSI has been
completely reorganized to emphasize information sharing and private-public sector cooperation.
Major advances included the development of the PSI Anti-counterfeiting Strategy with five
supporting programs and the Counterfeit Incident Reporting System. Mr. Kubic represents the
Institute at numerous international meetings, conferences and seminars. He has provided
testimony concerning the international nature of counterfeiting and its devastating impact before
senior government officials around the world. Among his varied responsibilities, he currently
serves on the Interpol Intellectual Property Crime Action Group and advises the Permanent
Forum against International Pharmaceutical Counterfeiting.
David Lansky, PhD, has served as the president of the Foundation of Accountability (FACCT) since
its inception in 1995. For more than twenty years, Lansky has been a proponent of a more
responsive and accountable health care system. He is a nationally recognized expert in
accountability and quality measurement and, as a result, has served as a board member or
advisor to numerous health care projects and programs. Some of these include the National
Quality Forum, Joint Commission on Accreditation of Healthcare Organizations, National Patient
Safety Foundation, The Leapfrog Group, and President Bush’s 2002 Economic Forum. Prior to
FACCT, Lansky was a senior policy analyst for the Jackson Hole Group during the national health
reform debate of 1993-94. He also led the Center for Outcomes Research and Education at
Oregon-based Providence Health System.
Yann Le Cam is the CEO of the European Organisation for Rare Diseases (EURORDIS). As a
patients’ associations advocate, he has dedicated the past 17 years to professional and personal
commitment to health and medical research nongovernmental organisations in France, Europe
and the United States in the fields of cancer, HIV/AIDS and rare diseases. He served as Director
General of the AIDES Fédération Nationale from 1992 to 1998. From 1995 to 1998 he served on
the National Council of Not-For-Profit Organisations (CNVA). In 1998, he joined the French
Neuromuscular Association (AFM), one of the largest patient organisations in Europe, well known
for its actions on genomic and gene therapy. His role as a special advisor was to stimulate public
health policy on rare diseases. In this capacity he founded, in February 2000, the Alliance
Maladies Rares, a national umbrella organisation of over 100 patient associations representing
over 900 rare diseases and over one million patients in France, and co-organised the first
conference on orphan drugs in Europe in October 1996 at the French Senate. Yann helped to
found EURORDIS in 1997 and contributed to the adoption of the European Regulation on Orphan
Drugs in December 1999. Yann was trained at the Institut Superior de Gestion (MBA, 1984) and at
the Centre de Perfectionnement des Affaires, Groupe HEC (Senior Executive MBA, 2000)
Prof. Carlos Martinez-Alonso is the President and Professor of investigation of immunology and
research at the Superior Council of Scientific Investigation (CSIC). He holds a degree in Chemistry
from the Madrid Complutense University. He has worked in the immunology department of
Puerta de Hiero Hospital, Madrid and also as an Associate Professor, Department of
Immunology, University of Umea, Sweden.
Mr. José Montilla is the Minister of Industry, Tourism and Commerce in the Spanish Government
since April 2004, as well as a senior member of two leading socialist parties – PSC and PSOE.
Prior to his nomination as the Minister, he was the President of the county council of Barcelona.
Mr. Montilla graduated from economics and law and joined public administration as a member of
the town council in Sant Joan Despi in 1979. In 1985 he became the president of the city council
in Cornella de Llobregat – the post that he held for 19 years.
Giovanni Moro is a political sociologist. He has carried out research and teaching activities in the
fields of public policies, governance, citizenship and civic activism, European issues and
corporate social responsibility. As an expert, he has cooperated with international and European
institutions. He is now visiting professor at the Faculty of Education of the University of Roma Tre
and is teaching at the post-degree course on “Citizenship and local welfare”, at the Faculty of
Statistics of Rome La Sapienza University. He is the author of the first general handbook on civic
participation published in Italy and has recently published a book on corporate social
responsibility together with Alessandro Profumo, the CEO of the second Italian bank, UniCredit.
From 1989 to 2002 he was the general secretary of Cittadinanzattiva, an Italian citizens’
movement founded in 1978. From 2001 to 2003 he directed, and is now program advisor, of the
European branch of Cittadinanzattiva, Active Citizenship Network. He is the president of
FONDACA, the Active Citizenship Foundation.
Dr. Ibra Ndoye is the Executive Secretary of National AIDS Council of Senegal. Gynecologist by
profession, he has authored and co-authored more than 100 publications on HIV/AIDS and STIs.
As the Manager of the National AIDS program of Senegal from 1986 to date, Dr Ndoye has
ensured a leadership in the widened epidemic answer to HIV/AIDS in Senegal and in the African
region. He also serves as African Regional Director of the International Union against Sexually
Transmitted Infections and the President of the African Union against Sexually Transmitted
Judith A. Oulton is Chief Executive Officer (CEO) of the Geneva-based International Council of
Nurses (ICN). ICN is a federation of 125 national nurses’ associations representing millions of
nurses worldwide. Prior to joining ICN, Oulton served for seven years as the Executive Director of
the Canadian Nurses Association (CNA) and the Canadian Nurses Protective Society. She was
also Chair of the Health Action Lobby (HEAL), a coalition of more than twenty Canadian health
and consumer organisations. Ms Oulton was previously Director of Strategic Planning for the
Department of Health and Community Services of the Province of New Brunswick, Canada.
Her career has included experience: in government as Senior Nursing Consultant with major
responsibility in hospital organisation and budgetary audits : in education as a professor in the
Nursing Faculty, University of New Brunswick: and in nursing administration and service in a
variety of clinical areas.
Fabio Pammolli is a Full Professor of Economics and Management, Faculty of Economics,
University of Florence. In the past, he served as a Director, I.M.T. Graduate Studies, The Sant’Anna
School of Advanced Studies (1989-1991). His research interests are in the fields of : Industrial
Dynamics and Market Regulation; Economics of Innovation; Economic Analysis of the
Pharmaceutical Industry. Prof. Pammolli is a member of the Commission on Intellectual Property
Rights, Innovation, and Public Health, World Health Organization. He is also Director at EPRIS
(European Pharmaceutical Innovation and Regulation Systems), as well as Founder and Director,
CERM (Magnetic Resonance Centre in Florence).
Since August 2003, Joy Phumaphi is the Assistant Director-General, Family and Community
Health cluster at the World Health Organization in Geneva, Switzerland. She was the Minister of
Health, Botswana and the Member of Parliament for Francistown East until July 2003.
Ms Phumaphi is a distinguished African American Institute Fellow and is a Commissioner in the
UN Secretary General’s Commission on HIV/AIDS and Governance in Africa. She is patron of the
following organizations: Women’s Shelter Project, Balekane Society, Botswana Widows’
Association, Botswana Christian Council AIDS Intervention Programme, Supa Ngwao Museum
and Motswedi Rehabilitation Centre. She also serves on the Board of Junior Achievement
Botswana. Ms Phumaphi has also served as a member of the UN Reference Group on
Economics (URGE) as well as a member of the UNDP Advisory Board for Africa.
Dr. Swati Piramal is a Director of Nicholas Piramal India Ltd where she looks after Research,
Intellectual Property Policy, Strategic Alliances and Communication. She is a Medical Doctor with
a Master’s Degree in Public Health from Harvard University, USA. She is on the Prime Minister’s
Governing Board for Scientific Research and the Economic and Biotechnology Councils for
Rajasthan and Maharashtra. Dr. Piramal is a member of the Commission on Intellectual Property
Rights, Innovation, and Public Health, World Health Organization and is actively involved in other
organisations including the World Economic Forum, Confederation of Indian Industry (CII)
Biotechnology and Life Sciences cell. She has been nominated one of the top 25 Most Powerful
Business Women in India. She is on the board of several biotechnology, insurance and
David Ridley, Ph.D., is an Assistant Professor of the Practice at the Fuqua School of Business at
Duke University. David’s research focuses on health sector business strategies, such as pricing
and market entry, and the impact of government regulations on those strategies. At Duke
University David has taught health economics, microeconomics, industrial organization, game
theory, and pharmaceutical strategy and management. David earned his Ph.D. in Economics at
Duke University in 2001.
Dr. Robert G. Ridley is the Director of the TDR Programme for Research and Training on Tropical
Diseases cosponsored by WHO, UNICEF, UNDP and the World Bank. Prior to being appointed
Director in June, Dr Ridley was the Coordinator of Product R&D within TDR, with overall
responsibility for drugs, vaccines and diagnostics. His background covers organic chemistry,
biochemistry and molecular biology. Between 1980 and 1992, he held positions at the University
of Malawi, McMaster University (Canada), and Edinburgh University (U.K.). He then moved to
Hoffmann-La-Roche, Switzerland, as Vice Director – Infectious Diseases Drug Discovery
department. In 1998, he joined TDR to manage drug discovery research. From there, he helped
launch the Medicines for Malaria Venture for which he acted as Chief Executive Officer in 1999. Dr
Ridley’s areas of interest and experience cover issues relating to the use of drugs, their financing
and provision in poor countries, as well as public sector interaction with the industry. He has
published widely on malaria research.
Jim Russo has been Executive Director of the Partnership for Quality Medical Donations since its
founding in 1999. PQMD’s mission is to raise standards of medical donations, document their
impacts and sponsor educational forums for the donations community at large. As the first
signatory to the World Health Organization Guidelines on drug donations, PQMD collaborates
with the World Health Organization, the World Bank and various academic institutions to study
donation practices, address problems and improve standards. The PQMD Board is composed of
ten leading pharmaceutical/medical equipment makers and twelve of the foremost humanitarian
agencies working in over 150 nations. PQMD meetings are noted for collegiality, open sharing
of ideas, and the start of joint projects involving organizations from diverse backgrounds.
Russo worked at PhRMA in Washgtion for 18 years and 18 more in policy development at
GlaxoSmithKline. He consulted for Novartis and various humanitarian agencies before being
asked the lead PQMD. He holds a Bachelor of Science degree from Temple University.
Ms Elena Salgado Méndez is the President of 11811Nueva Información Telefónica and a member
of the Board of Directors of Abertis Telecom. Throughout her professional career, she has hold
numerous posts in the Spanish government, including the Director-General for Personnel
Expenditure and Public Pensions in the Ministry of Economy and Finance, and the Secretary-
General for Communications in the Ministry of Public Works, Transport and Environment.
Ms Salgado Méndez has developed significant expertise in advanced technology sector,
resulting from her extensive experience as a senior executive in Arhur Andersen and Lenci
Consultong LC. She received her first university degree in industrial organisation from Universidad
Politécnica Madrid, Masters degree in quantitative management methods from Escuela
Organización Industrial as well as industrial engineer degree specialising in energy from
Universidad Politécnica de Madrid.
Peter Scheuer is the Executive Director of R&D-based Pharmaceutical Association in China since
1999. He played a key role in establishing and participating in working groups in drug regulatory
and medical affairs, price/reimbursement/bidding, intellectual property, communications, code
of pharmaceutical marketing practices, etc. and in organizing government/industry roundtables
and conferences: Reform of Pharmaceutical and Healthcare System (2002); Encouraging
Pharmaceutical R&D in Emerging Countries, Focus on China (2003) ; IFPMA 4th Asian Regulatory
Conference, Beijing (2004). From 1993 to 1999, Peter Scheuer was Legal Counsel to
U.S./European Companies on investment and litigation matters in China, including: largest
company in the world and companies ranked within the top five in pharmaceutical, IT and
telecom. From 1984 to 1992, he practiced as local government attorney in U.S.
Gabriella Stern is Dow Jones Newswires’ Senior Editor for Europe, the Middle East and Africa
(EMEA). She has overall responsibility for editorial operations in the region, which includes some
220 journalists and stretches from Dublin to Dubai. Dow Jones & Company acquired the news
division of vwd Vereinigte Wirtschaftsdienste GmbH in March 2004, which added another 100
journalists to Gabby’s team. Gabriella has two decades of journalistic experience, including stints
at the Associated Press while a student at Yale University, where she earned Bachelor’s and
Dr. Jeffrey L. Sturchio is Vice President, External Affairs, Human Health – Europe, Middle East &
Africa at Merck & Co., Inc., where he is responsible for developing, coordinating, and
implementing a range of health policy and communications initiatives for the region. He has been
centrally involved in Merck’s participation in the UN/Industry Accelerating Access Initiative to help
improve HIV/AIDS care and treatment in the developing world. He is also a member of the private
sector delegation to the Board of the Global Fund to Fight AIDS, TB and Malaria. Dr. Sturchio was
educated at Princeton (A.B., 1973) and the University of Pennsylvania (Ph.D., 1981). Before joining
Merck in 1989 after a brief sojourn at AT&T, he was an academic historian. His publications
include “What information do patients need about medicines? Perspectives from the
pharmaceutical industry” (with S. Bonaccorso), British Medical Journal 327 (11 October 2003):
863-864; and “Successful public-private partnerships in global health: lessons from the
MECTIZAN Donation Program,” (with B. Colatrella), in The Economics of Essential Medicines, ed.
by B. Granville (London: Royal Institute of International Affairs, 2002).
Born in Bangkok, Dr. Supachai received his Master’s Degree in Econometrics, Development
Planning and his Ph.D. in Economic Planning and Development at the Netherlands School of
Economics (now known as Erasmus University) in Rotterdam. Dr. Supachai began his
professional career at the Bank of Thailand in 1974, working in the Research Department, the
International Finance Division and the Financial Institutions Supervision Department. In 1986,
Dr. Supachai was elected a member of the Thai Parliament and was appointed Deputy Minister
of Finance. In 1988, he was appointed Director and Advisor, and subsequently President, of the
Thai Military Bank. In 1992, Dr. Supachai was appointed Senator and that same year he became
Deputy Prime Minister entrusted with oversight of the country’s economic and trade policy
making. In September 1999, he was elected Director General of World Trade Organization (WTO)
taking office on 1 September 2002. He has published a number of books including Globalization
and Trade in the New Millenium (2001) and China and WTO: Changing China Changing WTO
(2002, co-authored with Mark Clifford).
Dr. Björn Thylefors recently joined The Task Force for Child Survival and Development as Director
of the Mectizan Donation Program. Prior to joining the Mectizan Donation Program, Dr. Thylefors
was based in Geneva, Switzerland where he served as Programme Manager and Director of the
World Health Organization Programme for the Prevention of Blindness. During his career with
WHO he also served as Director of the WHO Department of Disability/Injury Prevention and
Rehabilitation. Dr. Thylefors has a wealth of experience in the field of international health,
particularly in onchocerciasis and the prevention of blindness. He received a Medical Diploma
from the University of Göteborg, a Swedish Diploma in Opthalmology, a Diploma in Epidemiology
from the Nordic School of Public Health, and an Academic Doctorate in Medicine from the
University of Göteborg. He has authored more than 70 scientific papers and articles.
Daniel Vasella, MD, is Chairman and CEO of Novartis AG. He was appointed Chairman in April
1999, having served as CEO and Head of the Group Executive Committee since the merger in
1996. His Novartis career began at Sandoz Pharma in 1988, where he assumed the position of
CEO in 1994. Prior to joining Sandoz, Dr. Vasella held a number of medical positions in Switzerland.
Dr. Vasella is a member of the Board of Directors of PepsiCo Inc. and of the Chairman’s Council of
DaimlerChrysler. He is also a member of the International Business Leaders Advisory Council for
the Mayor of Shanghai and of the International Board of Governors of the Peres Center for
Peace. In 2002 Dr. Vasella was awarded an honorary doctorate by the Faculty of Medicine of the
University of Basel.
Albert I. Wertheimer, PhD, MBA is Founding Director of the Center for Pharmaceutical Health
Services Research (PHSR) and a tenured professor at the School of Pharmacy, Temple
University, Philadelphia. Dr. Wertheimer is internationally recognized in the area of
pharmacoeconomics and outcomes research. He is Editor-in-Chief of the newly launched
Journal of Pharmaceutical Finance, Economics and Policy and author or co-editor of 21 books,
27 chapters and more than 340 journal articles. He had served as a consultant or lecturer in
55 countries and is active in managed care and international pharmacy, serving on numerous
task forces, committees and organizational advisory panels.
Roger L. Williams, M.D., Executive Vice President and CEO of the United States Pharmacopeia
(USP) since April 2000. Dr. Williams provides strategic leadership for USP and serves as chair of
the Council of Experts, USP’s scientific body. Dr. Williams received his undergraduate degree at
Oberlin College and his medical degree and training in internal medicine at the University of
Chicago. He completed his fellowship in clinical pharmacology at the University of California,
San Francisco, in 1974, where he continues as a faculty member. He joined the Food and Drug
Administration in 1990 as director of the Office of Generic Drugs in the Center for Drug Evaluation
and Research. He became deputy center director for pharmaceutical science in 1995,
overseeing the Center’s Office of New Drug Chemistry, Office of Generic Drugs, Office of Clinical
Pharmacology and Biopharmaceutics, and Office of Research and Testing. Dr. Williams is a
member of the medical honor societies Phi Beta Kappa and Alpha Omega Alpha, as well as
various scientific organizations.